ilaprazole has been researched along with Epstein-Barr Virus Infections in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhaduri-McIntosh, S; Bleck, CKE; Carter, C; Mannemuddhu, SS; Tjandra, N; Xu, H | 1 |
1 other study(ies) available for ilaprazole and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; A549 Cells; Antiviral Agents; Cell Line, Tumor; DNA-Binding Proteins; Endosomal Sorting Complexes Required for Transport; Epstein-Barr Virus Infections; HEK293 Cells; Herpesvirus 4, Human; Humans; Proton Pump Inhibitors; Rabeprazole; Transcription Factors; Viral Load; Virus Activation; Virus Latency; Virus Release; Virus Replication | 2021 |